8-K current report · filed Jul 29, 2026

Boston Scientific (BSX) 8-K Current Report: July 29, 2026

Item EX-99.1Item 2.02BSX overview

Short answer

Boston Scientific (BSX) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.

Boston Scientific 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1
  • Results update provides the latest view of Boston Scientific’s operating performance and financial condition

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net sales $5.442B, up 7.5% reported and 7.0% organic, reaching the top of reported guidance
  • GAAP EPS $0.61 and adjusted EPS $0.86, exceeding adjusted guidance of $0.82 to $0.84
  • Cardiovascular growth 7.8% organic, outpacing MedSurg at 5.4%, with APAC growth 11.2% and LACA growth 16.2%
  • Full-year guidance narrowed to 5.5% to 6.5% reported sales growth and adjusted EPS of $3.28 to $3.32
  • $1.5B MiRus investment secured approximately 34% ownership and an exclusive option for its TAVR business, expanding future cardiovascular opportunities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Boston Scientific 8-K filings

Get the next BSX 8-K as it lands

Follow BSX for push alerts, or ask the research agent what this filing means.